The constant and the sudden emergence of zoonotic human
and animal
viruses is a significant threat to human health, the world economy,
and the world food supply. This has necessitated the development of
broad-spectrum therapeutic strategies to combat these emerging pathogens.
Mechanisms that are essential for viral replication and propagation
have been successfully targeted in the past to develop broad-spectrum
therapeutics that can be readily repurposed to combat new zoonotic
pathogens. Because of the importance of viral RNA capping enzymes
to viral replication and pathogenesis, as well as their presence in
both DNA and RNA viruses, these viral proteins have been a long-standing
therapeutic target. Here, we use genome sequencing information and
yeast-based platforms (YeRC0M) to identify, characterize, and target
viral genome-encoded essential RNA capping enzymes from emerging strains
of DNA viruses, i.e., Monkeypox virus and African Swine Fever Virus,
which are a significant threat to human and domestic animal health.
We first identified and biochemically characterized these viral RNA
capping enzymes and their necessary protein domains. We observed significant
differences in functional protein domains and organization for RNA
capping enzymes from emerging DNA viruses in comparison to emerging
RNA viruses. We also observed several differences in the biochemical
properties of these viral RNA capping enzymes using our phenotypic
yeast-based approaches (YeRC0M) as compared to the previous in vitro
studies. Further, using directed evolution, we were able to identify
inactivation and attenuation mutations in these essential viral RNA
capping enzymes; these data could have implications on virus biocontainment
as well as live attenuated vaccine development. We also developed
methods that would facilitate high-throughput phenotypic screening
to identify broad-spectrum inhibitors that selectively target viral
RNA capping enzymes over host RNA capping enzymes. As demonstrated
here, our approaches to identify, characterize, and target viral genome-encoded
essential RNA capping enzymes are highly modular and can be readily
adapted for targeting emerging viral pathogens as well as their variants
that emerge in the future.